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Abstract
Background: CXCR4 is the receptor for chemokine CXCL12 and reportedly plays an important role in systemic
vascular repair and remodeling, but the role of CXCR4 in development of pulmonary hypertension and vascular
remodeling has not been fully understood.
Methods: In this study we investigated the role of CXCR4 in the development of pulmonary hypertension and
vascular remodeling by using a CXCR4 inhibitor AMD3100 and by electroporation of CXCR4 shRNA into bone
marrow cells and then transplantation of the bone marrow cells into rats.
Results: We found that the CXCR4 inhibitor significantly decreased chronic hypoxia-induced pulmonary
hypertension and vascular remodeling in rats and, most importantly, we found that the rats that were transplanted
with the bone marrow cells electroporated with CXCR4 shRNA had significantly lower mean pulmonary pressure
(mPAP), ratio of right ventricular weight to left ventricular plus septal weight (RV/(LV+S)) and wall thickness of
pulmonary artery induced by chronic hypoxia as compared with control rats.
Conclusions: The hypothesis that CXCR4 is critical in hypoxic pulmonary hypertension in rats has been
demonstrated. The present study not only has shown an inhibitory effect caused by systemic inhibition of CXCR4
activity on pulmonary hypertension, but more importantly also has revealed that specific inhibition of the CXCR4 in
bone marrow cells can reduce pulmonary hypertension and vascular remodeling via decreasing bone marrow
derived cell recruitment to the lung in hypoxia. This study suggests a novel therapeutic approach for pulmonary
hypertension by inhibiting bone marrow derived cell recruitment.
Introduction
Pulmonary hypertension caused by many chronic lung
diseases associated with prolonged hypoxia can result in
right ventricular hypertrophy and heart failure. Although
available treatments can improve prognosis, this disease
has been incurable with poor survival. An important
pathological feature of pulmonary hypertension is
increased medial thickening of pulmonary artery result-
ing from hypertrophy and hyperplasia of the pulmonary
artery smooth muscle cells (PASMC) [1-3].
The CXC chemokine receptor 4(CXCR4) is the recep-
tor for CXCL12, one of chemokines. Chemokines are a
family of small cytokines or proteins secreted by cells,
which have the ability to induce directed chemotaxis in
nearby responsive cells and therefore are also called che-
motactic cytokines. Chemokines include at least 40
ligands and 20 receptors [4]. According to amino acid
motif in their N-termini, chemokine ligands can be cate-
gorized into four types, C, CC, CXC and CX3C. The
CXC chemokines contain two N-terminal cysteins sepa-
rated by one amino acid, thus represented in its name
with an “X” [5,6]. CXCR4 is one of the seven CXC
motif chemokine receptors found so far.
The interaction of CXCR4 and its unique ligand
CXCL12 is essentialf o rm i g r a t i o no fp r o g e n i t o rc e l l s
during embryonic development of the cardiovascular,
hemopoietic and central nervous system. CXCR4 is also
involved in vascular remodeling [7-9]. Nemenoff and
colleagues reported that the CXCL12/CXCR4 axis is
involved in vascular remodeling and recruitment of
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that neointima formation and smooth muscle progenitor
cell mobilization were inhibited by CXCR4 inhibitor
after arterial injury [11]. Zernecke et al. found that the
CXCL12/CXCR4 axis played an important role in neoin-
timal hyperplasia and recruitment of smooth muscle
progenitor cells after arterial injury [12]. Satoh and col-
leagues [13] observed that pravastatin attenuated
hypoxic pulmonary hypertension was accompanied by a
decrease in plasma level of CXCL12 and in accumula-
tion of CXCR4
+ cells in mouse lungs.
The CXCL12/CXCR4 axis was originally described as
a regulator of cell interaction in the immune system
[14] mediating leukocyte migration to inflammatory area
[15]. This axis was also involved in regulation of wide
range of cell migration or mobilization [16-19]. In addi-
tion, it has been reported that CXCR4 plays a vital role
in regulation of stem/progenitor cell migration and
development in cancer, nervous system and heart repair
after myocardial infarction [20-25]. Young et al. [26]
recently used a neonatal mouse model of pulmonary
hypertension and found that the inhibition of CXCR4
activity significantly decreased hypoxia-induced pulmon-
ary hypertension. Interestingly, Gambaryan et al. most
recently reported that AMD3100, an antagonist of
CXCR4, prevented in part pulmonary hypertension, vas-
cular remodeling and right ventricular hypertrophy
induced by chronic hypoxia in mice [27]. However, the
role of CXCR4 in pulmonary hypertension and remodel-
ing has not been completely understood.
In this study we used a CXCR4 inhibitor, AMD3100,
in rats to determine the role of CXCR4 in development
of pulmonary hypertension and vascular remodeling. In
addition, we electroporated CXCR4 shRNA into bone
marrow cells and then transplanted the bone marrow
cells with CXCR4 shRNA into rats to investigate the
effect of CXCR4 on bone marrow cell migration in
hypoxia-induced pulmonary hypertension. We hypothe-
sized that inhibition of systemic CXCR4 through admin-
istration of AMD3100 will inhibit hypoxia-induced
pulmonary hypertension and vascular remodeling in rats
and that specific inhibition of the CXCR4 in bone mar-
row cells also will impact development of pulmonary
hypertension and vascular remodeling induced by
chronic hypoxia.
Materials and methods
Chemicals
AMD3100 octahydrochloride hydrate (AMD3100) (1,1’-
[1,4-Phenylenebis(methylene)]bis-1,4,8,11-tetraazacyclo-
tetradecane octahydrochloride) was obtained from
Sigma. CXCR4 shRNA plasmid, a plasmid vector con-
taining the shRNA under control of the U1 promoter,
was obtained from SABiosciences (Frederick, MD).
Animals
Animal experiments were approved by the Subcommit-
tee on Research Animal Care at Massachusetts General
Hospital. Wild type male Sprague-Dawley (SD) rats
(Charles River Laboratories, Wilmington, MA), weighing
150 ~ 200 grams, were used as bone marrow cell trans-
plant recipients. Male SD background transgenic rats
containing green fluorescent protein gene (SD-Tg(GFP)
2BalRrrc, termed as SD-GFP) were obtained from
Resource and Research Center at University of Missouri
(Columbia, MO) and used as bone marrow cell donors.
CXCR4 inhibitor and hypoxic pulmonary hypertension
Rats were placed in a hypoxia chamber and treated with
a CXCR4 inhibitor AMD3100. The CXCR4 inhibitor
was administered by a mini osmotic pump (DURECT
Corporation, Cupertine, CA) implanted subcutaneously
at dose of 10 mg/kg/day for 14 days. The control ani-
mals received normal saline by the same size mini
pump. After two weeks of exposure to hypoxia and
treatment with the CXCR4 inhibitor, the rats were
removed from hypoxia for measurements.
Electroporation of bone marrow cells with CXCR4 shRNA
and hypoxic pulmonary hypertension
This experiment included bone marrow cell harvest,
CXCR4 shRNA electroporation, transplantation and
then pulmonary hypertension development. Bone mar-
row cells were harvested from donor SD-GFP rats fol-
lowing the methods described by Spees [28] and
Kroeger [29]. Briefly, SD-GFP rats were sacrificed by
CO2 exposure and femurs and tibias of the rats were
dissected sterilely. After cutting each end of the femurs
and tibias to expose marrow, we placed each bone into
a 1.5 ml sterile eppendorf tube and centrifuged it for
1 min at 1200 rpm. Bone marrow pellets were obtained
and resuspended with PBS and then filtered through 70
micro cell strainers. Followed by centrifugation, the
bone marrow cells were resuspended with medium and
the number of the bone marrow cells was counted for
transplantation. Electroporation of CXCR4 shRNA plas-
mid into bone marrow cells was performed following
published methods [30-33]. Briefly, the harvested bone
marrow cells (5 × 10
6 cells per rat) were resuspended
w i t hs e r u mf r e em e d i u ma t1×1 0
6 cells/ml and then
placed into an electroporation cuvette. After adding
CXCR4 shRNA plasmid (2 μM) to the cuvette and pla-
cing the cuvette in an electroporator chamber (Bio-Rad,
GenePulser Xcell), the cells were then electroporated
following the manufacturer’s instruction. After electro-
poration, the cell suspension was transfered to a centri-
fuge tube, spun down and resuspended with medium
for transplantation. The efficiency of the shRNA delivery
was detected by Western blot. To allow transplantation
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irradiated with a dose of 11 Gy. Following irradiation,
the harvested bone marrow cells were injected into the
rat via tail vein (5 × 10
6 cells per rat). After transplanta-
tion, the rats were recovered in normoxia for 3 weeks
before exposure to hypoxia.
Hypoxia exposure
H y p o x i ae x p o s u r ew a sp e rformed as previously
described [34-37]. Briefly, animals were weighed and
placed in a tightly sealed hypoxia chamber or exposed
to normoxia for two weeks. Oxygen concentration was
maintained at 10% by controlling the flow rates of com-
pressed air and N2. Concentrations of O2 and CO2 in
chamber were checked daily.
Measurement of mean pulmonary artery pressure
The measurement for mean pulmonary artery pressure
(mPAP) was performed as described previously [34-37].
Briefly, after 14 days in the chamber the animals were
removed and anesthetized with intraperitoneal ketamine
(80 mg/kg) and diazepam (5 mg/kg). Animals were
placed on a warming blanket to maintain body tempera-
ture at 37°C. mPAP was measured via a catheter (0.012”
× 0.021” silicone tubing) passed through the right exter-
nal jugular vein and right ventricle. Once the mPAP was
obtained, the animals were sacrificed with 200 mg/kg of
pentobarbital and used immediately for the determina-
tion of right ventricular hypertrophy, hematocrit, and
lung pathology.
Measurement of right ventricular hypertrophy
The ventricles and septum of the animals were collected
and the wet and dry ventricle and septal weight were
obtained by drying them for 24 hours at 60°C. Then a
ratio of right ventricle to left ventricle plus septum
weight (RV/(LV+S)) was calculated for determination of
right ventricular hypertrophy [34-37].
Measurement of pulmonary vascular remodeling
Elastic fibers in pulmonary arteries were stained for
measurement of medial wall thickness of pulmonary
arteries. Percent medial wall thickness of pulmonary
arteries was used for evaluation of pulmonary artery
remodeling as previously described [36,37]. The percent
wall thickness was calculated as average diameter of the
external elastic lamina minus the average diameter of
internal elastic lamina divided by the average diameter
of external elastic lamina. A computer imaging analysis
was applied for measurement of wall thickness. Images
of individual pulmonary arteries were captured using a
digital camera, mounted on a light microscope and
linked to a computer. All the muscular arteries between
50 μma n d1 5 0μm in diameter in slides were analyzed
in this study. The detail on measurement of wall thick-
ness had been described previously [35,36].
Hematocrit analysis
Blood samples were centrifuged in microcapillary tubes
for 3 min and the hematocrit was read directly.
Western blot
Total protein was isolated from rat bone marrow cells,
rat lungs and pulmonary arteries isolated from rats that
received bone marrow cell transplantation. Western blot
was performed as described previously [34,35,38,39].
Antibodies included CXCR4 (Abcam, Cambridge, MA),
c-kit (Santa Cruz Biotechnology, Inc., Santa Cruz, CA),
GFP and GAPDH (Abcam, Cambridge, MA).
Analysis of bone marrow cell engraftment
Bone marrow white blood cell (WBC) count and flow
cytometry were performed for this analysis. The WBC
numbers were determined by directly counting WBC
number in bone marrow under the microscope by using
a hemacytometer after staining the bone marrow cells
with crystal violet. For flow cytometry analysis, bone
marrow mononuclear cells were collected by using den-
sity gradient centrifugation media (Ficoll-Paque Pre-
mium, GE Healthcare Bio-Sciences AB, Uppsala,
Sweden). Mononuclear cells were stained with primary
antibodies, anti-mouse/rat CD34 (R&D Systems, Inc.
Minneapolis, MN) and anti-rat CD45 (BioLegend, San
Diego, CA). Following incubation for 30 minutes and
washing with PBS, the cells were incubated with second-
ary antibody for 30 minutes and then flow cytometric
analysis was performed with a 7 Laser SORP BD LSR II.
Data were collected with DIVA software on LSR II and
analyzed with FlowJo v8.8.6.
Statistical Analysis
Statistics was performed using the computer program
Statview (SAS Institute Inc., Cary, NC) with the analysis
of variance (ANOVA). If ANOVA was significant, multi-
ple comparisons were made among groups using the
Fisher protected least significant difference test. All
values were expressed as the mean ± standard error.
Significance was set at p < 0.05.
Results
Administration of CXCR4 inhibitor significantly decreased
hypoxia-induced pulmonary artery pressure and right
ventricular hypertrophy in rats
After two weeks of exposure to hypoxia, control rats
developed pulmonary hypertension, showing a signifi-
cant increase in pulmonary artery pressure (mPAP) as
compared with the normoxic rats. However, the pul-
monary artery pressure was significantly decreased in
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pared with the hypoxia controls (Figure 1A). The CXCR4
inhibitor also significantly decreased right ventricular
hypertrophy, showing a decrease in the ratio of RV/(LV
+S) in the rats treated with the CXCR4 inhibitor as com-
pared with the hypoxic control animals (Figure 1B).
Interestingly, we found that exposure to hypoxia signifi-
cantly increased right ventricular weight (Figure 1C) and
decreased left ventricular plus septal weight (Figure 1D),
which resulted in an increase in the ratio of RV/(LV+S)
in hypoxic control animals, but the whole heart weight
was not different between the hypoxic control and
hypoxia plus CXCR4 inhibitor treatment (Figure 1E).
Administration of CXCR4 inhibitor significantly decreased
hypoxia-induced pulmonary artery remodeling in rats
Exposure to hypoxia significantly induced vascular
remodeling, showing an increase in medial wall thick-
ness of pulmonary arteries in hypoxic control group as
compared with the normoxic controls. Treatment of
rats with the CXCR4 inhibitor significantly prevented
the wall thickness of pulmonary arteries induced by
hypoxia (Figure 2A). Interestingly, administration of the
CXCR4 inhibitor significantly attenuated body weight
loss in animals under hypoxia as compared with the
hypoxic control rats (Figure 2B). In addition, hypoxia
significantly increased hematocrit values in all rats as
compared with their normoxic controls, but no signifi-
cant difference was observed between the hypoxic
groups (Figure 2C).
Electroporation of bone marrow cells with CXCR4 shRNA
significantly decreased hypoxia-induced pulmonary
hypertension and right ventricular hypertrophy in rats
After transplantation with bone marrow cells electropo-
rated with CXCR4 shRNA and recovery under normoxia
for three weeks (all rats that did not receive bone mar-
row cell transplantation died within one week after irra-
diation), the rats were placed in the hypoxia chamber
for two weeks to induce pulmonary hypertension. We
found that hypoxia-induced pulmonary hypertension
was significantly decreased in the rats transplanted with
CXCR4 shRNA bone marrow cells, showing decreased
mean pulmonary artery pressure (Figure 3A) and
decreased ratio of RV/(LV+S) (Figure 3B) as compared
with the rats receiving scrambled shRNA in bone mar-
row cells or the rats injected with bone marrow cells
without shRNA.
Electroporation of bone marrow cells with CXCR4 shRNA
significantly decreased hypoxia-induced vascular
remodeling
We found that transplantation with bone marrow cells
electroporated with CXCR4 shRNA significantly
decreased hypoxia-induced vascular remodeling, show-
ing a decrease in percent wall thickness of pulmonary
arteries (Figure 4A) as compared with other hypoxic
control groups. In addition, we found that all animals
with bone marrow transplantation had decreased body
weight as compared with the rats without bone marrow
transplantation (Figure 4B). Interestingly, as shown in
the figures (Figure 3A &3B and 4A), the irradiated rats
developed lower pulmonary hypertension as compared
with non-irradiated hypoxic animals, but there was no
significant difference between them. Hypoxia also signif-
icantly increased hematocrit values in all hypoxic ani-
mals (Figure 4C).
Effect of CXCR4 shRNA delivery on CXCR4 expression in
bone marrow cells
To determine the efficiency of the CXCR4 shRNA
delivery in bone marrow cells, we measured CXCR4
expression in primary bone marrow cells and bone
marrow cells harvested from recipient rats. Following
electroporation of bone marrow cells with CXCR4
shRNA plasmid, we transplanted the bone marrow
cells into rats and, at the same time, left some cells
and cultured them for 48 hours for analysis of CXCR4
expression in primary bone marrow cells. In addition,
we harvested bone marrow cells from the rats that
received bone marrow cell transplantation at end of
recovery (week 3) and at end of hypoxia exposure
(week 5) respectively and measured CXCR4 expression.
We found more than 90% inhibition at 48 hours after
electroporation in primary bone marrow cells, more
than 70% inhibition on week 3 and more than 40%
inhibition on week 5 in the harvested bone marrow
cells with CXCR4 shRNA electroporation from the
recipient rats (Figure 5).
Effect of CXCR4 shRNA delivery on bone marrow-derived
progenitor cell migration
To demonstrate the effect of CXCR4 shRNA delivery on
bone marrow cell migration, we detected GFP, a marker
for donor bone marrow cells, expression in rat lung. We
found a significant decrease in GFP protein expression
in the lungs from rats that received CXCR4 shRNA
bone marrow cells (Figure 6A) as compared with other
hypoxic animals. In order to further determine whether
CXCR4 inhibition in bone marrow cells affected bone
marrow-derived progenitor cell migration, we measured
c-kit, a hematopoietic progenitor marker, expression in
pulmonary artery isolated from rats that received bone
marrow cells. We found a significant decrease in c-kit
expression in the pulmonary artery from the rats that
received the bone marrow cells electroporated with
CXCR4 shRNA as compared with other hypoxic control
groups (Figure 6B).
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Figure 1 Effect of CXCR4 inhibitor on pulmonary artery pressure and right ventricular hypertrophy induced by chronic hypoxia in
rats. (A) mPAP, showing representative tracings of pulmonary artery pressure (upper panel) and quantitative data (lower panel). (B-E) Right
ventricular hypertrophy, showing data on RV/(LV+S) (B), right ventricular weight (C), left ventricular plus septal weight (D) and whole heart
weight (E). *p < 0.05 as compared with other groups and # p > 0.05 as compared with normoxic control rats. n = 5 rats for each group.
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Figure 2 Effect of CXCR4 inhibitor on wall thickness of pulmonary arteries induced by chronic hypoxia in rats.( A )W a l lt h i c k n e s s
showing quantitative data on percent wall thickness (%WT) (left panel) and representative microphotographs (right panel). TA = terminal
bronchial arterioles; I A = intra-acinous arterioles. (B) Body weight change. *p < 0.05 as compared with other groups. (C) hematocrit. *p < 0.05 as
compared with normoxia. n = 5 rats for each group.
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marrow cells
To investigate the effect of CXCR4 shRNA delivery on
bone marrow cell engraftment. We measured white
blood cells (WBC) in harvested bone marrow cells by
counting the number of WBC and analyzed expression
of CD34 and CD45 in bone marrow cells by flow cyto-
metry. We found that delivery of CXCR4 shRNA
decreased the bone marrow cell engraftment in this
study (Table 1), although the change was not significant.
Discussion
I nt h i ss t u d yw ef o u n dt h a taC X C R 4i n h i b i t o rs i g n i f i -
cantly inhibited hypoxia-induced pulmonary hyperten-
sion (Figure 1A), right ventricular hypertrophy (Figure
1B) and vascular remodeling of pulmonary arteries
(Figure 2A) in rats. We also found that inhibition of the
CXCR4 in bone marrow cells by shRNA electroporation
also significantly attenuated hypoxia-induced pulmonary
hypertension (Figure 3A), right ventricular hypertrophy
(Figure 3B) and vascular remodeling (Figure 4A). The
delivery of CXCR4 shRNA by electroporation signifi-
cantly inhibited CXCR4 expression in bone marrow
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and also significantly decreased GFP expression in rat
lungs (Figure 6A) and decreased c-kit expression in rat
pulmonary artery (Figure 6B).
Recently we found that CXCR4 was expressed in pul-
monary artery smooth muscle cells and that hypoxia
increased CXCR4 expression in the lungs from mice
with pulmonary hypertension and that a CXCR4 inhibi-
tor AMD3100 significantly inhibited pulmonary artery
smooth muscle cell proliferation (unpublished data). We
thereafter investigated the effect of the CXCR4 inhibitor
on hypoxia-induced pulmonary hypertension in rats in
t h i ss t u d y .A ss h o w ni nt h er e s u l t s ,t w ow e e k so ft r e a t -
ment with the CXCR4 inhibitor significantly decreased
hypoxia-induced pulmonary pressure, right ventricular
hypertrophy and vascular remodeling of pulmonary
arteries in rats. These results demonstrated that CXCR4
plays a critical role in development of pulmonary hyper-
tension and vascular remodeling in rats. Toshner et al.
recently reported up-regulated CXCL12 and CXCR4 in
lung tissue from patients with idiopathic pulmonary
hypertension [40]. Young et al. [26] and Gambaryan et
al. [27] recently reported that inhibition of CXCR4
activity significantly decreased hypoxia-induced pulmon-
ary hypertension in mice, but Young et al. only used
neonatal mice [26]. The results from our study further
demonstrated the effect of CXCR4 in development of
pulmonary hypertension and vascular remodeling in
chronically hypoxic rats.
An important pathological feature of pulmonary
hypertension is vascular remodeling of the pulmonary
arteries. One of the unsolved questions regarding the
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Figure 6 Effect of CXCR4 shRNA delivery on bone marrow cell
migration to rat lung: (A) GFP expression. Proteins were isolated
form rat lungs and Western blot was performed for analysis of GFP
protein expression. Quantitative data (upper panel), setting hypoxia
BMC as 1, and representative images (lower panel). *p < 0.05 as
compared with other groups. (B) c-kit expression. Proteins were
isolated form rat pulmonary artery and Western blot was performed
for analysis of c-kit expression. Quantitative data (upper panel),
setting normoxia control as 1, and representative images (lower
panel). *p < 0.05 as compared with other hypoxia groups. # p >
0.05 as compared with normoxia control. n = 3 for each groups.
BMC = transplantation of bone marrow cells without shRNA, BMC
+S-RNA = transplantation of bone marrow cells with scrambled
shRNA, BMC+ CXCR shRNA = transplantation of bone marrow cells
with CXCR4 shRNA.
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ary hypertension is whether the vascular remodeling is
caused by bone marrow-derived progenitor cells, which
migrate to the wall of pulmonary arteries via blood-
stream [1]. Although some work has been done on bone
marrow stem cells and pulmonary hypertension in dif-
ferent laboratories [28,41,42], the results were not con-
sistent. We in this study investigated relationship
between bone marrow cell migration and development
of pulmonary hypertension. We electroporated CXCR4
shRNA into bone marrow cells to inhibit CXCR4 and
then transplanted the bone marrow cells into lethally
irradiated rats. After two weeks of exposure to hypoxia,
the rats transplanted with CXCR4 shRNA bone marrow
cells had significantly lower pulmonary artery pressure,
right ventricular hypertrophy and wall thickness of pul-
monary arteries as compared with hypoxic control ani-
mals that received scrambled shRNA in bone marrow
cells or were injected with bone marrow cells without
shRNA. Because electroporation of bone marrow cells
with the CXCR4 shRNA only affected CXCR4 expression
in bone marrow cells, this finding provided direct evi-
dence that CXCR4 is involved in regulation of bone mar-
row cell migration during development of pulmonary
hypertension and vascular remodeling induced by
hypoxia. This finding also demonstrated the involvement
of bone marrow cells in pulmonary hypertension and
vascular remodeling. Although Young et al. reported that
inhibition of CXCR4 activity by AMD3100 decreased
hypoxia-induced pulmonary hypertension and vascular
remodeling in neonatal mice, which was accompanied
with decreased expression of some stem cell markers in
the mouse lungs, they did not show any direct evidence
to demonstrate the relationship between bone marrow
cell migration and the development of pulmonary hyper-
tension. Therefore, this is the first study to show that
migration inhibition of bone marrow cells by CXCR4
shRNA inhibits development of hypoxia-induced pul-
monary hypertension and vascular remodeling. Electro-
poration is simple and reliable method for delivery of
specific gene into primary bone marrow cells [30-33].
Therefore, electroporation of bone marrow cells with
specific genes would be a useful method for investigation
of bone marrow cells and pulmonary hypertension.
It has been reported that CXCL12/CXCR4 axis plays
an important role in cell recruitment [7-9], including
mobilization of bone marrow cells [43-45]. In this study,
we observed that inhibition of the CXCR4 in bone mar-
row cells significantly decreased hypoxia-induced pul-
monary hypertension and vascular remodeling, which
indicated that bone marrow cell migration played a role
in the development of pulmonary hypertension. To
demonstrate the effect of CXCR4 shRNA delivery on
bone marrow cell migration, we investigated expression
of GFP, a marker for donor bone marrow cells. We
found a significant decrease in GFP expression in the
lung from rats that had been transplanted with CXCR4
shRNA bone marrow cells. To further determine
whether inhibition of CXCR4 in bone marrow cells
impacted bone marrow-derived progenitor cell migra-
tion, we examined a hematopoietic progenitor marker,
c-kit, in pulmonary artery isolated from rats. We found
a significant decrease in c-kit expression in the pulmon-
ary artery from rats that received the bone marrow cells
electroporated with CXCR4 shRNA as compared with
other hypoxic control groups, which indicated the deliv-
ery of CXCR4 shRNA in bone marrow cells also affected
bone marrow-derived progenitor cell migration.
Recently, Gambaryan et al. [27] reported that the effect
of CXCR4 antagonist on hypoxia-induced pulmonary
hypertension and vascular remodeling in mice was asso-
ciated with a significantly decreased number of perivas-
cular c-kit
+ hematopoietic progenitor cells. These data
on c-kit expression together with the result from GFP
expression demonstrated that CXCR4 knock down by
shRNA decreased bone marrow-derived progenitor cell
migration to the lungs under hypoxia.
Since a recent report has shown that inhibition of sys-
temic CXCR4 through the delivery of AMD3100 could
have had an effect on SDF-1 expression, we analyzed
SDF-1 expression in the lung of rats that received
AMD3100. We did not find significant change in SDF-1
expression in the animals that received AMD3100 in
this study (data not shown).
Studies have shown that CXCR4 expression can alter
bone marrow engraftment and that high expression of
CXCR4 is required for engraftment [46-48]. In this
study, we observed a decrease in WBC and in CD34
and CD45 expression in bone marrow cells, although
the change was not significant. Interestingly, Monaco
et al. [49] found that CXCR4 was not critical for
engraftment of AML CD34
+ cells in NOD/SCID mice.
T h e yf o u n dt h a ta c u t em y e l o i dl e u k e m i a( A M L )C D 3 4
+
cells with virtually absent CXCR4 expression were able
to engraft, but the cells with high expression of CXCR4
did not. They also found that anti-CXCR4 antibody
failed to block the engraftment of AML cells onto
NOD/SCID mice. In addition, a recent study showed
Table 1 Effect of CXCR4 shRNA on bone marrow cell
engraftment
Hypoxia
Control Control BMC BMC/S-R BMC/CXCR4
WBC(x10
6) 22.5 ± 1.5 24.6 ± 2.2 24.5 ± 2.4 23.2 ± 2.0 21.3 ± 2.1 Δ
CD34
+(%) 38.5 ± 2.4 39.1 ± 2.0 38.7 ± 1.9 38.2 ± 3.4 35.1 ± 3.0 Δ
CD45
+(%) 32.2 ± 1.8 31.4 ± 3.4 32.3 ± 1.3 31.4 ± 3.1 30.0 ± 2.1 Δ
Δp > 0.05 as compared with other groups. n = 3 for each group.
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improved donor hematopoietic cell engraftment in a
mouse model [50]. The different results observed in
separate laboratories suggest that CXCR4 is important,
but may not be critical for regulating engraftment of
bone marrow cells.
In conclusion, this study found that CXCR4 plays an
important role in development of hypoxia-induced pul-
monary hypertension and vascular remodeling. We also
found that specific inhibition of the CXCR4 in bone
marrow cells attenuated hypoxia-induced pulmonary
hypertension and vascular remodeling. Our data demon-
strated the importance of CXCR4 in the development of
chronic hypoxic pulmonary hypertension and vascular
remodeling in rats and demonstrated the role of CXCR4
in regulation of bone marrow cell migration in that pro-
cess. This study suggests a novel therapeutic approach
for pulmonary hypertension by inhibiting bone marrow
cell recruitment.
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